Kathrin Jansen, Senior Vice President and Head of Vaccine Research and Development at Pfizer, talks about the challenges of creating a new maternal vaccine for respiratory syncytial virus, also known as RSV, currently being administered to pregnant women in trials, in the hopes of protecting their infants.